News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
553,649 Results
Type
Article (46744)
Company Profile (120)
Press Release (506774)
Multimedia
Podcasts (147)
Webinars (20)
Section
Business (145987)
Career Advice (2423)
Deals (28143)
Drug Delivery (144)
Drug Development (68674)
Employer Resources (158)
FDA (15997)
Job Trends (12071)
News (265986)
Policy (29934)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2327)
Academic (1)
Accelerated approval (40)
Adcomms (36)
Allergies (142)
Alliances (36278)
ALS (169)
Alzheimer's disease (1726)
Antibody-drug conjugate (ADC) (328)
Approvals (16150)
Artificial intelligence (523)
Autoimmune disease (170)
Automation (36)
Bankruptcy (312)
Best Places to Work (9199)
BIOSECURE Act (23)
Biosimilars (196)
Biotechnology (70)
Bladder cancer (163)
Brain cancer (56)
Breast cancer (599)
Cancer (4686)
Cardiovascular disease (423)
Career advice (2052)
Career pathing (40)
CAR-T (267)
CDC (67)
Celiac Disease (1)
Cell therapy (741)
Cervical cancer (36)
Clinical research (59069)
Collaboration (1553)
Company closure (4)
Compensation (1182)
Complete response letters (78)
COVID-19 (2726)
CRISPR (94)
C-suite (825)
Cystic fibrosis (143)
Data (5993)
Decentralized trials (2)
Denatured (33)
Depression (151)
Diabetes (490)
Diagnostics (5586)
Digital health (38)
Diversity (8)
Diversity, equity & inclusion (43)
Drug discovery (238)
Drug pricing (224)
Drug shortages (33)
Duchenne muscular dystrophy (248)
Earnings (62627)
Editorial (69)
Employer branding (20)
Employer resources (142)
Events (82366)
Executive appointments (910)
FDA (19153)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (21)
Funding (1307)
Gene editing (205)
Generative AI (45)
Gene therapy (633)
GLP-1 (1082)
Government (4215)
Grass and pollen (8)
Guidances (378)
Healthcare (14907)
HIV (69)
Huntington's disease (52)
IgA nephropathy (87)
Immunology and inflammation (294)
Immuno-oncology (67)
Indications (116)
Infectious disease (3003)
Inflammatory bowel disease (191)
Inflation Reduction Act (14)
Influenza (114)
Intellectual property (246)
Interviews (454)
IPO (14140)
IRA (58)
Job creations (3173)
Job search strategy (1673)
JPM (69)
Kidney cancer (19)
Labor market (85)
Layoffs (619)
Leadership (43)
Legal (7025)
Liver cancer (91)
Longevity (15)
Lung cancer (623)
Lymphoma (362)
Machine learning (42)
Management (52)
Manufacturing (765)
MASH (172)
Medical device (11601)
Medtech (11650)
Mergers & acquisitions (15013)
Metabolic disorders (1349)
mRNA (188)
Multiple sclerosis (150)
NASH (22)
Neurodegenerative disease (337)
Neuropsychiatric disorders (101)
Neuroscience (2975)
Neurotech (1)
NextGen: Class of 2026 (5002)
Non-profit (3200)
Now hiring (31)
Obesity (678)
Opinion (286)
Ovarian cancer (154)
Pain (195)
Pancreatic cancer (229)
Parkinson's disease (287)
Partnered (26)
Patents (497)
Patient recruitment (488)
Peanut (56)
People (44345)
Pharmaceutical (33)
Pharmacy benefit managers (33)
Phase 1 (17747)
Phase 2 (25566)
Phase 3 (20922)
Pipeline (5481)
Policy (348)
Postmarket research (2208)
Preclinical (7218)
Press Release (31)
Prostate cancer (255)
Psychedelics (57)
Radiopharmaceuticals (254)
Rare diseases (934)
Real estate (4309)
Recruiting (65)
Regulatory (23342)
Reports (41)
Research institute (2125)
Resumes & cover letters (405)
Rett syndrome (29)
RNA editing (16)
RSV (77)
Schizophrenia (156)
Series A (227)
Series B (178)
Service/supplier (8)
Sickle cell disease (101)
Special edition (27)
Spinal muscular atrophy (141)
Sponsored (47)
Startups (2797)
State (1)
Stomach cancer (21)
Supply chain (107)
Tariffs (101)
The Weekly (113)
Vaccines (1115)
Venture capital (97)
Weight loss (477)
Women's health (81)
Worklife (23)
Date
Today (104)
Last 7 days (819)
Last 30 days (2660)
Last 365 days (28267)
2026 (4576)
2025 (28435)
2024 (31442)
2023 (35036)
2022 (45111)
2021 (48538)
2020 (45562)
2019 (36242)
2018 (27423)
2017 (27840)
2016 (25833)
2015 (28007)
2014 (21815)
2013 (17835)
2012 (18995)
2011 (19432)
2010 (17561)
Location
Africa (686)
Alabama (69)
Alaska (6)
Arizona (237)
Arkansas (11)
Asia (32476)
Australia (5685)
California (10750)
Canada (2569)
China (943)
Colorado (417)
Connecticut (473)
Delaware (309)
Europe (79379)
Florida (1637)
Georgia (331)
Hawaii (4)
Idaho (39)
Illinois (766)
India (58)
Indiana (437)
Iowa (22)
Japan (420)
Kansas (106)
Kentucky (29)
Louisiana (19)
Maine (73)
Maryland (1320)
Massachusetts (7771)
Michigan (277)
Minnesota (561)
Mississippi (5)
Missouri (119)
Montana (12)
Nebraska (23)
Nevada (114)
New Hampshire (62)
New Jersey (2888)
New Mexico (15)
New York (2778)
North Carolina (1378)
North Dakota (8)
Northern California (5366)
Ohio (291)
Oklahoma (15)
Oregon (34)
Pennsylvania (2062)
Puerto Rico (18)
Rhode Island (32)
South America (1047)
South Carolina (65)
South Dakota (1)
Southern California (4184)
Tennessee (154)
Texas (1596)
United States (37520)
Utah (276)
Virginia (252)
Washington D.C. (73)
Washington State (843)
West Virginia (4)
Wisconsin (113)
Wyoming (1)
553,649 Results for "transgene s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
October 13, 2025
·
6 min read
Press Releases
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
October 20, 2025
·
9 min read
Press Releases
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
July 28, 2025
·
6 min read
Transgene’s Combined General Meeting of May 5, 2023
The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held at 9:00 a.m. at the Company’s headquarters.
May 5, 2023
·
4 min read
Press Releases
Verinomics Introduces Transgene-Free Gene Editing and Genomic-Driven Accelerated Breeding Platforms for Specialty Crops
March 10, 2025
·
4 min read
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
Regulatory
Disc’s FDA Rejection Raises Questions About Commissioner’s Vouchers
FDA vouchers are normally a coveted prize for biopharma companies, but a surprise rejection for Disc Medicine’s rare disease drug has biopharma reconsidering.
February 18, 2026
·
4 min read
·
Dan Samorodnitsky
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have had a hand in; Compass Pathways posts new late-stage data on its psilocybin-based depression drug; CDC is once again leaderless.
February 18, 2026
·
1 min read
·
Heather McKenzie
Press Releases
Kraig Biocraft Laboratories Announces the Launch of Advanced Gene-Splicing Program and New Transgenics
April 16, 2025
·
3 min read
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.
January 2, 2026
·
5 min read
·
Annalee Armstrong
1 of 55,365
Next
